• Health Care M&A Deals, September 18, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal... Read More »
  • MetLife Acquires Versant Health

    MetLife, Inc. (NYSE: MET) has entered the healthcare M&A market. Last week, the company announced the acquisition of Versant Health, the parent company of Davis Vision and Superior Vision, two major vision care and insurance brands with a combined 35 million members. Centerbridge Partners and an investor group including FFL Partners are... Read More »
  • CloudMD Expands Patient Engagement Portfolio

    CloudMD Software & Services Inc. (OTCMKTS: DOCRF) just keeps rolling out new deals and acquisitions. The company has been very active this year, with six acquisitions on the books so far across various sectors, according to search results in our Deal Search Online database. Last week, CloudMD acquired Toronto-based iMD Health Global Corp. for... Read More »
  • Trulieve Cannabis Boosts Its Market Reach

    Trulieve Cannabis Corp. (OTC: TCNNF), a vertically integrated “seed-to-sale” company and the first licensed medical cannabis company in the state of Florida, announced two new transactions last week. M&A activity in the medical marijuana market has been quiet throughout 2020 and 2019, after experiencing somewhat of a boom in 2018,... Read More »
  • A Busy Week for Home Health & Hospice Deals

    It was a busy week for home health & hospice (HH&H) transactions. Results from our Deal Search Online database show there were four announced last week alone, half of September’s total so far. Half of the deals were completed by private equity-backed companies, which highlights the continued interest in HH&H from PE firms. Jet... Read More »
Gilead Bets $21 Billion on Oncology Market

Gilead Bets $21 Billion on Oncology Market

Gilead Sciences, Inc. (NASDAQ: GILD) kicked off this week with a multi-billion acquisition of Immunomedics (NASDAQ: IMMU). The pharmaceutical giant reached an agreement to buy Immunomedics for $21 billion, or $88 per share, a 108% premium to Immunomedics’ closing price on September 11, 2020. Immunomedics generated trailing 12-month revenues of $20.37 million. The deal will be funded through approximately $15 billion in cash on hand, as well as approximately $6 billion in newly issued debt. Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology focused on researching therapeutics for hard-to-treat cancers, and is most known for its product Trodelvy, an ADC... Read More »
Gilead Bets $21 Billion on Oncology Market

Nestle Health Science Strikes New Multibillion Deal

Nestle Health Science, a global business unit of Nestle S.A. (SWX: NESN), has announced a takeover of California-based Aimmune Therapeutics, Inc. (NASDAQ: AIMT) valued at $2.6 billion. Aimmune Therapeutics is a biopharmaceutical company developing and commercializing oral treatments for potentially life-threatening food allergies. Nestle Health Science previously had a total investment in Aimmune of $473 million, an approximate 25.6% equity ownership stake, and will pay $34.50 per share in cash for the remainder, or a 174% premium to Aimmune’s closing share price on August 28 of $12.60. Aimmune reported a trailing 12-month revenue of $575,000. Nestle Health Science is acquiring... Read More »
JNJ Announces Multibillion-Dollar Takeover of Momenta

JNJ Announces Multibillion-Dollar Takeover of Momenta

Johnson & Johnson (NYSE: JNJ) made a splash in the healthcare M&A market last week with its acquisition of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). The global pharmaceutical giant announced on August 19 it is paying $6.5 billion in cash, or $52.50 per share, for Momenta, a 70.4% premium over Momenta’s August 18 closing price. Momenta reported a trailing 12-month revenue of $30.07 million. On the day of the announcement, Momenta’s share price jumped 69%. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of JNJ to broaden its market reach in immune-mediated diseases and drive further growth through expansion into autoantibody-driven... Read More »
Gilead Bets $21 Billion on Oncology Market

AstraZeneca Strikes Another Collaboration with Daichi Sankyo

AstraZeneca plc (NYSE: AZN) has struck a new global development and commercialization agreement with Daiichi Sankyo Company (OTCMKTS: SKYF) that could be worth up to $6 billion. The agreement focuses on DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), and potential new medicine for the treatment of multiple tumor types.  AstraZeneca will pay $1 billion in staged payments over 24 months, and up to $5 billion for the successful achievement of regulatory approvals and sales-related milestones.  The companies will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain... Read More »
Gilead Bets $21 Billion on Oncology Market

Sanofi Inks New Licensing Deal

Just weeks following its agreement with Translate Bio (NASDAQ: TBIO) for COVID-19 vaccine development, Sanofi (NYSE: SNY) has a new agreement with Kymera Therapeutics Inc. Sanofi and Kymera are signing a multi-program collaboration to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. IRAK4 is believed to play a key role in multiple immune-inflammatory diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant... Read More »
Sanofi Pasteur Jumps Into the COVID-19 Vaccine Race

Sanofi Pasteur Jumps Into the COVID-19 Vaccine Race

Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY) has expanded its partnership with Translate Bio (NASDAQ: TBIO ) to produce a COVID-19 vaccine. The two companies are pursuing novel mRNA vaccines aimed at broadly addressing current and future infectious diseases, evaluating multiple COVID-19 vaccine candidates. They hope to conduct human clinical trials in Q4:2020 but are also advancing an mRNA vaccine development candidate against influenza through preclinical studies with clinical trial initiation anticipated in mid-year 2021. The original agreement dates back to 2018, when Translate Bio and Sanofi Pasteur entered into a collaboration and exclusive license agreement to develop... Read More »